Phase III Clinical Study of Recombinant Erythropoiesis Stimulating Protein Injection (rESP) in the Treatment of Anemia in Hemodialysis Patients With Chronic Renal Failure

NCT05211167 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Kidney Failure, Chronic
Hemodialysis

Interventions

DRUG: Human Erythropoiesis Injection (CHO cell)
DRUG: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.